Top 10 Pharma Drug Discovery and Delivery Capital Raises and Investors in the U.S. – July 16th to August 31st, 2025
Several interesting transactions closed in the Pharma Drug Discovery and Delivery sector over the past two weeks. If you would like more info or would like to discuss the capital raising market for your company, please contact me.
PIPE
- NRx Pharmaceuticals, clinical-stage, small-molecule pharmaceutical firm that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases, received $6.5 million of development capital from B Group Capital led consortium of investors on August 18, 2025.
- PharmaCyte Biotech, clinical-stage biotechnology platform that focuses on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, received $7 million of development capital from investors on August 20, 2025.
Merger/Acquisition
- Aster Insights, health informatics-based tool that accelerates the discovery, development and delivery of personalized medicine for cancer therapies, was acquired by Zephyr AI on August 26, 2025.
- Capstan Therapeutics, biotechnology platform that expands therapeutic options through targeted in vivo Ribonucleic Acid (RNA) technologies, was acquired by AbbVie for $2.1 billion on August 19, 2025.
Later Stage VC
- Angiex, vascular-targeted biotherapeutics for the treatment of solid cancers and other diseases of pathological angiogenesis, raised $10.98 million of venture funding from William Paseman and other investors on August 14, 2025.
- Pattern, single-cell microbiology antimicrobial treatment that simplifies antibiotic selection for life-threatening infections, raised $44.22 million of Series D venture funding from investors on August 18, 2025, putting the company’s pre-money valuation at $60.78 million.
Early Stage VC
- Bacchus Therapeutics, targeted cancer therapies that exploit cancer’s altered metabolic pathways for treatment purposes, raised venture funding from Virginia Innovation Partnership Corporation in August 2025.
- Igniton, cognitive enhancement supplements that improve longevity, cognitive functions, memory, and personal energy, raised $6 million of venture funding from investors on August 8, 2025.
Seed Round
- Axo, next-generation neural interface technologies that restore neurological function and enable novel neural data acquisition, raised pre-seed funding from Neo in August 2025.
- Plexiform Bioscience, non-invasive retinal treatments that improve eye health, raised $1.34 million of seed funding from investors on July 18, 2025.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmaceuticals #biotechnology #pharmadrugdiscovery #pharmadrugdelivery
Please contact me if you have any questions or would like to discuss your capital raise:
Email: druddy@castleplacement.com
(C) (406) 868-3218
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.











